Exposure of human prostaspheres to bisphenol a epigenetically regulates SNORD family noncoding RNAs via histone modification

Endocrinology

Volumn 156, Issue 11, 2015, Pages 3984-3995

  Ho, Shuk Mei ^a,b,c,d   Cheong, Ana ^a,b   Lam, Hung Ming ^a,b,g   Hu, Wen Yang ^e,f   Shi, Guang Bin ^e,f   Zhu, Xuegong ^a,b   Chen, Jing ^a,b   Zhang, Xiang ^a,b   Medvedovic, Mario ^a,b,c   Leung, Yuet Kin ^a,b,c   Prins, Gail S ^e,f  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b Department of Environmental Health   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^d Veteran's Hospital Medical Center   (United States)

^e TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' ISOPROPYLIDENEDIPHENOL; ESTRADIOL; GENOMIC DNA; SMALL NUCLEOLAR RNA; SMALL UNTRANSLATED RNA; SNORD PROTEIN; SNORD116 PROTEIN; SNORD117 PROTEIN; SNORD58A PROTEIN; SNORD59A PROTEIN; SNORD82 PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG; BENZHYDRYL DERIVATIVE; ESTROGEN; HISTONE; LYSINE; PHENOL DERIVATIVE; UNTRANSLATED RNA;

ARTICLE; CELL COUNT; CELL GROWTH; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE REPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HISTONE METHYLATION; HISTONE MODIFICATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROSTASPHERE; PROSTATE CANCER; PROTEIN METHYLATION; PROTEIN MOTIF; REPRODUCTIVE TOXICITY; RNA PROCESSING; STEM CELL; UPREGULATION; CLUSTER ANALYSIS; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; EPITHELIUM CELL; GENETIC EPIGENESIS; GENETICS; HISTONE CODE; METABOLISM; METHYLATION; PATHOLOGY; PROSTATE; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BENZHYDRYL COMPOUNDS; CLUSTER ANALYSIS; CPG ISLANDS; DNA METHYLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; EPITHELIAL CELLS; ESTRADIOL; ESTROGENS; ESTROGENS, NON-STEROIDAL; HISTONE CODE; HISTONES; HUMANS; LYSINE; MALE; METHYLATION; PHENOLS; PROSTATE; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, UNTRANSLATED; STEM CELLS; TRANSCRIPTOME;

EID: 84943609451     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2015-1067     Document Type: Article

References (50)

1. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer. 2004;101:2371-2490.
2. Mullins JK, Loeb S. Environmental exposures and prostate cancer. Urol Oncol. 2012;30:216-219.
3. Hu WY, Shi GB, Hu DP, Nelles JL, Prins GS. Actions of estrogens and endocrine disrupting chemicals on human prostate stem/progenitor cells and prostate cancer risk. Mol Cell Endocrinol. 2012; 354:63-73.
4. Keri RA, Ho SM, Hunt PA, Knudsen KE, Soto AM, Prins GS. An evaluation of evidence for the carcinogenic activity of bisphenol A. Reprod Toxicol. 2007;24:240-252.
5. Rubin BS. Bisphenol A: an endocrine disruptor with widespread exposure and multiple effects. J Steroid Biochem Mol Biol. 2011; 127:27-34.
6. Liao C, Kannan K. Widespread occurrence of bisphenol A in paper and paper products: implications for human exposure. Environ Sci Technol. 2011;45:9372-9379.
7. Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Exposure of the U. S. population to bisphenol A and 4-tertiary-octylphenol: 2003-2004. Environ Health Perspect. 2008;116:39-44.
8. Song Y, Hauser R, Hu FB, Franke AA, Liu S, Sun Q. Urinary concentrations of bisphenol A and phthalate metabolites and weight change: a prospective investigation in US women. Int J Obes (Lond). 2014;38:1532-1537.
9. Sun Q, Cornelis MC, Townsend MK, et al. Association of urinary concentrations of bisphenol A and phthalate metabolites with risk of type 2 diabetes: a prospective investigation in the Nurses' Health Study (NHS) and NHSII cohorts. Environ Health Perspect. 2014; 122:616-623.
10. Melzer D, Osborne NJ, Henley WE, et al. Urinary bisphenol A concentration and risk of future coronary artery disease in apparently healthy men and women. Circulation. 2012;125:1482-1490.
11. Tarapore P, Ying J, Ouyang B, Burke B, Bracken B, Ho SM. Exposure to bisphenol A correlates with early-onset prostate cancer and promotes centrosome amplification and anchorage-independent growth in vitro. PLoS One. 2014;9:e90332.
12. Bakshi S, Zhang X, Godoy-Tundidor S, et al. Transcriptome analyses in normal prostate epithelial cells exposed to low-dose cadmium: oncogenic and immunomodulations involving the action of tumor necrosis factor. Environ Health Perspect. 2008;116:769-776.
13. Lam YW, Yuan Y, Isaac J, Babu CV, Meller J, Ho SM. Comprehensive identification and modified-site mapping of S-nitrosylated targets in prostate epithelial cells. PLoS One. 2010;5:e9075.
14. Hess-Wilson JK, Webb SL, Daly HK, et al. Unique bisphenol A transcriptome in prostate cancer: novel effects on ER/3 expression that correspond to androgen receptor mutation status. Environ Health Perspect. 2007;115:1646-1653.
15. Wetherill YB, Hess-Wilson JK, Comstock CE, et al. Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther. 2006;5:3181-3190.
16. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS. Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant 4. Cancer Res. 2006;66:5624-5632.
17. Tang WY, Morey LM, Cheung YY, Birch L, Prins GS, Ho SM. Neonatal exposure to estradiol/bisphenol A alters promoter meth-ylation and expression of Nsbp1 and Hpcal1 genes and transcriptional programs of Dnmt3a/b and Mbd2/4 in the rat prostate gland throughout life. Endocrinology. 2012;153:42-55.
18. Walker CL, Ho SM. Developmental reprogramming of cancer susceptibility. Nat Rev Cancer. 2012;12:479-486.
19. Frank SB, Miranti CK. Disruption of prostate epithelial differentiation pathways and prostate cancer development. Front Oncol. 2013;3:273.
20. Prins GS. Developmental estrogenization of the prostate gland. In: Naz RK, ed. Prostate: Basic and Clinical Aspects. Boca Raton, FL: CRC Press, Inc; 1997:247-263.
21. Prins GS, Birch L, Habermann H, et al. Influence of neonatal estrogens on rat prostate development. Reprod Fertil Dev. 2001;13:241-252.
22. Shah M, Allegrucci C. Stem cell plasticity in development and cancer: epigenetic origin of cancer stem cells. Subcell Biochem. 2013; 61:545-565.
23. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON. Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci USA. 2007;104:181-186.
24. Hu WY, Shi GB, Lam HM, et al. Estrogen-initiated transformation of prostate epithelium derived from normal human prostate stem-progenitor cells. Endocrinology. 2011;152:2150-2163.
25. Prins GS, Hu WY, Shi GB, et al. Bisphenol A promotes human prostate stem-progenitor cell self-renewal and increases in vivo carcinogenesis in human prostate epithelium. Endocrinology. 2014; 155:805-817.
26. Makarova JA, Ivanova SM, Tonevitsky AG, Grigoriev AI. New functions of small nucleolar RNAs. Biochemistry (Mosc). 2013;78: 638-650.
27. Tsao SW, Mok SC, Fey EG, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res. 1995;218:499-507.
28. Sartor MA, Leikauf GD, Medvedovic M. LRpath: a logistic regression approach for identifying enriched biological groups in gene expression data. Bioinformatics. 2009;25:211-217.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-AAC(T)) method. Methods. 2001;25:402-408.
30. Bibikova M, Barnes B, Tsan C, et al. High density DNA methylation array with single CpG site resolution. Genomics. 2011;98:288-295.
31. Morris TJ, Butcher LM, Feber A, et al. ChAMP: 450k Chip analysis methylation pipeline. Bioinformatics. 2014;30:428-430.
32. Zhu X, Leav I, Leung YK, et al. Dynamic regulation of estrogen receptor-/3 expression by DNA methylation during prostate cancer development and metastasis. Am J Pathol. 2004;164:2003-2012.
33. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427-1431.
34. Zhu X, Asa SL, Ezzat S. Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clin Cancer Res. 2008;14:1984-1996.
35. Ouyang B, Leung YK, Wang V, et al. a-Methylacyl-CoA racemase spliced variants and their expression in normal and malignant prostate tissues. Urology. 2011;77:249. e241-247.
36. Young MD, Willson TA, Wakefield MJ, et al. ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activity. Nucleic Acids Res. 2011;39:7415-7427.
37. Kim J, Kim H. Recruitment and biological consequences of histone modification of H3K27me3 andH3K9me3. ILARJ. 2012;53:232-239.
38. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature. 2006;444:444-454.
39. Avissar-Whiting M, Veiga KR, Uhl KM, et al. Bisphenol A exposure leads to specific microRNA alterations in placental cells. Reprod Toxicol. 2010;29:401-406.
40. Tilghman SL, Bratton MR, Segar HC, et al. Endocrine disruptor regulation of microRNA expression in breast carcinoma cells. PLoS One. 2012;7:e32754.
41. Bhan A, Hussain I, Ansari KI, Bobzean SA, Perrotti LI, Mandal SS. Bisphenol-A and diethylstilbestrol exposure induces the expression of breast cancer associated long noncoding RNA HOTAIR in vitro and in vivo. J Steroid Biochem Mol Biol. 2014;141:160-170.
42. Alonso-Magdalena P, Ropero AB, Soriano S, et al. Bisphenol-A acts as a potent estrogen via non-classical estrogen triggered pathways. Mol Cell Endocrinol. 2012;355:201-207.
43. Wu H, D'Alessio AC, Ito S, et al. Dual functions of Tet1 in tran-scriptional regulation in mouse embryonic stem cells. Nature. 2011; 473:389-393.
44. Callihan P, Mumaw J, Machacek DW, Stice SL, Hooks SB. Regulation of stem cell pluripotency and differentiation by G protein coupled receptors. Pharmacol Ther. 2011;129:290-306.
45. Duker AL, Ballif BC, Bawle EV, et al. Paternally inherited microde-letionat15q11. 2 confirmsasignificant role for the SNORD116 C/D box snoRNA cluster in Prader-Willi syndrome. Eur J Hum Genet. 2010;18:1196-1201.
46. Powell WT, Coulson RL, Crary FK, et al. A Prader-Willi locus ln-cRNA cloud modulates diurnal genes and energy expenditure. Hum Mol Genet. 2013;22:4318-4328.
47. Dong XY, Rodriguez C, Guo P, et al. SnoRNA U50 is a candidate tumor-suppressor gene at 6q14. 3 with a mutation associated with clinically significant prostate cancer. Hum Mol Genet. 2008;17: 1031-1042.
48. Tanaka R, Satoh H, Moriyama M, et al. Intronic U50 small-nucle-olar-RNA (snoRNA) host gene of no protein-coding potential is mapped at the chromosome breakpoint t(3;6)(q27;q15) of human B-cell lymphoma. Genes Cells. 2000;5:277-287.
49. Martens-Uzunova ES, Hoogstrate Y, Kalsbeek A, et al. C/D-box snoRNA-derived RNA production is associated with malignant transformation and metastatic progression in prostate cancer. Oncotarget. 2015;6:17430-17444.
50. Sahoo T, del Gaudio D, German JR, et al. Prader-Willi phenotype caused by paternal deficiency for the HBII-85 C/D box small nucle-olar RNA cluster. Nat Genet. 2008;40:719-721.